×
ACADIA Pharmaceuticals Price/Book Ratio 2010-2024 | ACAD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
ACADIA Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
View More
ACADIA Pharmaceuticals Price/Book Ratio 2010-2024 | ACAD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
ACADIA Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$155.8B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$116B
Gilead Sciences (GILD)
$111.9B
CSL (CSLLY)
$86.5B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.8B
Argenex SE (ARGX)
$35.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$23B
Illumina (ILMN)
$21.7B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$14.7B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.5B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.6B
Exelixis (EXEL)
$9.9B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.7B
Revolution Medicines (RVMD)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.9B
Ascendis Pharma (ASND)
$7.4B